Oral creatine supplementation in Duchenne muscular dystrophy: A clinical and 31P magnetic resonance spectroscopy study

Neurological Research

Volumn 22, Issue 2, 2000, Pages 145-150

  Felber, Stephan ^a,b   Skladal, Daniela ^a   Wyss, Markus ^a   Kremser, Christian ^a   Koller, Arnold ^b   Sperl, Wolfgang ^c  

^a Dept Radiol II and Magnetic Reson ^*  (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c Children's Hospital Salzburg   (Austria)

Author keywords

31P magnetic resonance spectroscopy; Creatine; Duchenne muscular dystrophy; Muscle disease; Supplementation

Indexed keywords

CREATINE; CREATINE KINASE; DYSTROPHIN; LACTATE DEHYDROGENASE; MALTODEXTRIN; PLACEBO;

ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ASSAY; EXERCISE; GASTROCNEMIUS MUSCLE; HUMAN; MALE; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE;

EID: 0034111130     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1080/01616412.2000.11741051     Document Type: Article

References (13)

1. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The phosphocreatine circuit for cellular energy homeostasis. Biochem J 1992; 281: 21-40
2. Wyss M, Smeitink J, Wevers RA, Wallimann T. Mitochondrial creatine kinase: A key enzyme of aerobic energy metabolism. Biochem Biophys Acta 1992; 1102: 119-166
3. Wyss M, Felber S, Skladal D, Koller A, Kremser CI, Sperl W. The therapeutic potential of oral creatine supplementation in muscle disease. Med Hypotheses 1998; 51: 333-336
4. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev Accepted for publication
5. Bittner RE, Shorny S, Ferlings R, Sperl WI, Kress W, Muller CR, Cremer M, Leger JJ, Voit T. Sarcolemmal expression of dystrophin C-terminus but reduced expression of 6Q-dystrophin-related protein in two DMD patients with large deletions of the dystrophin gene. Neuromusc Disord 1995; 5: 81-92
6. Seo Y, Murakami M, Watan H, Imai Y, Yoshizaki K, Nishikawa H, Morimoto T. Intracellular pH determination by a 31P-NMR technique. The second dissociation constant of phosphoric acid in a biological system. J Biochem 1983; 94: 729-734
7. Delanghe J, De Slypere J-P, De Buyzere M, Robbrecht J, Wieme R, Vermeulen A. Normal reference values for creatine, creatinine, and carnitine are lower in vegetarians. Clin Chem 1989; 35: 1802-1803
8. Griffith RD, Cady EB, Edwards RH, Wilkie DR. Muscle energy metabolism in Duchenne dystrophy studied by 31P-NMR: Controlled trials show no effect of allopurinol or ribose. Muscle Nerve 1985; 8: 760-767
9. Barany M, Siegel I, Venkatasubramanian P, Mok E, Wilbur A. Human leg neuromuscular diseases: P-31 NMR spectroscopy. Radiology 1989; 172: 503-508
10. Younkin D, Berman P, Sladky J, Chee C, Bank W, Chance B. 31P NMR studies in Duchenne muscular dystrophy: Age-related metabolic changes. Neurology 1987; 37: 165-169
11. Kemp G, Taylor D, Dunn J, Frostic S, Radda G. Cellular energetics of dystrophic muscle. J Neurol Sci 1993; 116: 201-206
12. Heckmatt JZ, Hyde SA, Gabain A, Dubowitz V. Therapeutic trial of isaxonine in Duchenne muscular dystrophy. Muscle Nerve 1988; 11: 838-847
13. 2+ handling and survival in mdx skeletal muscle cells. Abstract Book of the 30th Annual Meeting of the Swiss Societies for Experimental Biology 1998: 20